Scarica l'app Stockscreener
36.44
0.77%
0.28
Precedente Chiudi:
$36.16
Aprire:
$36.05
Volume 24 ore:
1.24M
Relative Volume:
0.53
Capitalizzazione di mercato:
$3.53B
Reddito:
$7.50M
Utile/perdita netta:
$-383.17M
Rapporto P/E:
-7.7453
EPS:
-4.7048
Flusso di cassa netto:
$-307.84M
1 W Prestazione:
-3.01%
1M Prestazione:
-37.87%
6M Prestazione:
-37.60%
1 anno Prestazione:
-8.07%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$35.06
$37.79
Portata 52W:
$35.06
$72.66
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
36.44 | 3.53B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-06 | Ripresa | Guggenheim | Buy |
| 2026-09-18 | Downgrade | Deutsche Bank | Buy → Hold |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD - Investing.com
Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD By Investing.com - Investing.com Canada
XENE Assumed by Guggenheim -- Buy Rating Assigned with Price Tar - GuruFocus
Xenon Pharmaceuticals stock gets 28,350 awards for new hires - AD HOC NEWS
President of Xenon Pharmaceuticals Picks Up 88% More Stock - Simply Wall Street
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Eight new Xenon employees get options to buy shares at $38.93 - Stock Titan
Xenon Pharmaceuticals (XENE) Shares Rise After CEO and CFO Buy $1.7M in Stock - GuruFocus
Xenon rises on insider buys from CEO and CFO (XENE:NASDAQ) - Seeking Alpha
Xenon Pharmaceuticals (XENE) CFO Thomas Kelly Buys 15,000 Shares in Open-Market Purchase - GuruFocus
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says - Yahoo Finance
Xenon Pharmaceuticals Insider Bought Shares Worth $1,121,400, According to a Recent SEC Filing - Yahoo Finance
At $37.316 each, CFO Kelly buys 15,000 Xenon Pharmaceuticals (XENE) shares. - Stock Titan
At $37.38 a share, Xenon Pharmaceuticals (XENE) CEO Ian Mortimer buys company stock. - Stock Titan
Gross margin % of Xenon Pharmaceuticals Inc. – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.70 after FDA filing - AD HOC NEWS
Total common shares outstanding of Xenon Pharmaceuticals Inc. – HAN:XP0 - TradingView
Xenon Pharmaceuticals Inc. Balance Sheet – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.30 after trial pause - AD HOC NEWS
Xenon Pharmaceuticals Inc. (XENE) Interactive Stock ChartYahoo Finance - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc. (XENE) stock price, news, quote and history - Yahoo Finance Australia
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law - Business Wire
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback? - Yahoo Finance
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) - PR Newswire
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate (XENE) - Seeking Alpha
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors - GlobeNewswire
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors - GlobeNewswire
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit - GlobeNewswire
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment - Yahoo Finance
Xenon will present a drug being developed for epilepsy and two types of depression - Stock Titan
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data - Yahoo Finance
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - benzinga.com
Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold From Buy, Adjusts PT to $46 From $90 - Yahoo Finance
XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial - Yahoo Finance
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause - Yahoo Finance
Wedbush Cuts Price Target on Xenon Pharmaceuticals to $55 From $71, Keeps Outperform Rating - Yahoo Finance
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain. - Barron's
Xenon Announces Azetukalner NDA Submission to FDA for Focal - GlobeNewswire
Xenon Pharmaceuticals: Epilepsy Got It To $59; Depression Has To Take It From Here - Seeking Alpha
Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care - Yahoo Finance
A drugmaker plans a 30-minute healthcare talk in Boston Sept. 9. Xenon will present. - Stock Titan
Xenon to Present at Wells Fargo Healthcare Conference - Yahoo Finance
Behavioral Patterns of XENE and Institutional Flows - Stock Traders Daily
Xenon Pharmaceuticals stock holds firm as analysts stick to buy ratings - ad-hoc-news.de
Xenon Pharmaceuticals (XENE) CMO sells 7,068 shares in Rule 10b5-1 plan trades around $61. - Stock Titan
Xenon Pharma (NASDAQ: XENE) holder to sell 7,068 shares - Stock Titan
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Barchart.com
What Xenon Pharmaceuticals (XENE)'s New Azetukalner Phase 3 Epilepsy Data Means For Shareholders - Yahoo Finance
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xenon Pharmaceuticals Inc Azioni (XENE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Sep 30 '26 |
Buy |
37.38 |
30,000 |
1,121,400 |
49,923 |
| Svoronos Dawn | Director |
Sep 01 '26 |
Option Exercise |
8.15 |
5,144 |
41,924 |
31,373 |
| CHRISTOPHER KENNEY | Officer |
Aug 28 '26 |
Proposed Sale |
61.93 |
7,068 |
437,721 |
0 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer |
Aug 28 '26 |
Sale |
60.25 |
7,068 |
425,829 |
2 |
| STEVEN GANNON | Director |
Aug 11 '26 |
Proposed Sale |
64.06 |
10,000 |
640,553 |
0 |
| GANNON STEVEN | Director |
Aug 11 '26 |
Sale |
64.06 |
10,000 |
640,550 |
1,870 |
| GARY PATOU | Director |
Jun 05 '26 |
Proposed Sale |
52.99 |
1,322 |
70,053 |
0 |
| PATOU GARY | Director |
Jun 05 '26 |
Sale |
53.14 |
1,322 |
70,251 |
24,896 |
| Cannon Gillian | Director |
Jun 05 '26 |
Sale |
53.14 |
1,190 |
63,237 |
1,455 |
| GILLIAN CANNON | Director |
Jun 05 '26 |
Proposed Sale |
52.99 |
1,190 |
63,058 |
0 |
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):